SHBs Mitigates Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1/MEK/ERK Signaling Pathway.

Summary: Liver cancer is one of the most common cancers in the world, and it is often linked to the Hepatitis B virus. A drug called sorafenib is usually the best treatment for advanced liver cancer. However, Hepatitis B can make the cancer resist this drug so it stops working. Researchers found that a specific protein from the virus, called SHBs, stops the cancer cells from dying when treated with sorafenib. It does this by turning on a survival signal inside the cells. By understanding how this virus protein works, scientists hope to find new ways to block it and make cancer treatments work better for patients with Hepatitis B.